The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I multicenter, open-label study to establish the maximum tolerated dose (MTD) of trifluridine/tipiracil (TAS-102) and oxaliplatin combination in patients (pts) with metastatic colorectal cancer (mCRC).
 
Antoine Hollebecque
Honoraria - Merck Serono
Consulting or Advisory Role - Amgen
Travel, Accommodations, Expenses - Amgen; SERVIER
 
Aitana Calvo
No Relationships to Disclose
 
Thierry Andre
Honoraria - Baxter; BAYER; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; MSD Oncology; Novartis; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche/Genentech
 
Guillem Argiles
No Relationships to Disclose
 
Andres Cervantes
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck Serono; Novartis; Roche/Genentech; SERVIER; Takeda
Speakers' Bureau - Merck Serono; Roche
Research Funding - Merck Serono; Roche; SERVIER
Travel, Accommodations, Expenses - Roche
 
Catherine Leger
Employment - SERVIER
 
Aude Valette
Employment - SERVIER
 
Nadia Amellal
Employment - SERVIER
 
Ronan Fougeray
Employment - SERVIEr
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Celgene; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; Sanofi; Symphony Evolution; Taiho Pharmaceutical; Takeda